Subthalamic Nucleus Stimulation Impairs Motivation: Implication for Apathy in Parkinson's Disease.
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
25
03
2019
revised:
13
11
2019
accepted:
25
11
2019
pubmed:
14
1
2020
medline:
28
4
2021
entrez:
14
1
2020
Statut:
ppublish
Résumé
Apathy is one of the most disabling neuropsychiatric symptoms in Parkinson's disease (PD) patients and has a higher prevalence in patients under subthalamic nucleus deep brain stimulation. Indeed, despite its effectiveness for alleviating PD motor symptoms, its neuropsychiatric repercussions have not yet been fully uncovered. Because it can be alleviated by dopaminergic therapies, especially D We longitudinally assessed the motivational effects of chronic subthalamic nucleus deep brain stimulation by using innovative wireless microstimulators, allowing continuous stimulation of the subthalamic nucleus in freely moving rats and a pharmacological therapeutic approach. We showed for the first time that subthalamic nucleus deep brain stimulation induces a motivational deficit in naive rats and intensifies those existing in a rodent model of PD neuropsychiatric symptoms. As reported from clinical studies, this loss of motivation was fully reversed by chronic treatment with pramipexole, a D Taken together, these data provide experimental evidence that chronic subthalamic nucleus deep brain stimulation by itself can induce loss of motivation, reminiscent of apathy, independently of the dopaminergic neurodegenerative process or reduction in dopamine replacement therapy, presumably reflecting a dopaminergic-driven deficit. Therefore, our data help to clarify and reconcile conflicting clinical observations by highlighting some of the mechanisms of the neuropsychiatric side effects induced by chronic subthalamic nucleus deep brain stimulation. © 2020 International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Apathy is one of the most disabling neuropsychiatric symptoms in Parkinson's disease (PD) patients and has a higher prevalence in patients under subthalamic nucleus deep brain stimulation. Indeed, despite its effectiveness for alleviating PD motor symptoms, its neuropsychiatric repercussions have not yet been fully uncovered. Because it can be alleviated by dopaminergic therapies, especially D
METHODS
We longitudinally assessed the motivational effects of chronic subthalamic nucleus deep brain stimulation by using innovative wireless microstimulators, allowing continuous stimulation of the subthalamic nucleus in freely moving rats and a pharmacological therapeutic approach.
RESULTS
We showed for the first time that subthalamic nucleus deep brain stimulation induces a motivational deficit in naive rats and intensifies those existing in a rodent model of PD neuropsychiatric symptoms. As reported from clinical studies, this loss of motivation was fully reversed by chronic treatment with pramipexole, a D
CONCLUSIONS
Taken together, these data provide experimental evidence that chronic subthalamic nucleus deep brain stimulation by itself can induce loss of motivation, reminiscent of apathy, independently of the dopaminergic neurodegenerative process or reduction in dopamine replacement therapy, presumably reflecting a dopaminergic-driven deficit. Therefore, our data help to clarify and reconcile conflicting clinical observations by highlighting some of the mechanisms of the neuropsychiatric side effects induced by chronic subthalamic nucleus deep brain stimulation. © 2020 International Parkinson and Movement Disorder Society.
Substances chimiques
Dopamine Agonists
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
616-628Subventions
Organisme : Institut National de la Santé et de la recherche Médicale
Pays : International
Organisme : Fondation de France
Pays : International
Organisme : Région Rhône-Alpes
ID : Arc no. 2
Pays : International
Organisme : Neurodis
Pays : International
Organisme : Grenoble Alpes Université
Pays : International
Organisme : CNRS
Pays : International
Organisme : Aix-Marseille Université
Pays : International
Organisme : France Parkinson
Pays : International
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 International Parkinson and Movement Disorder Society.
Références
Benabid AL, Chabardes S, Mitrofanis J, Pollak P. Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease. Lancet Neurol 2009;8(1):67-81.
Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8(5):464-474.
Castrioto A, Lhommee E, Moro E, Krack P. Mood and behavioural effects of subthalamic stimulation in Parkinson's disease. Lancet Neurol 2014;13(3):287-305.
Marin RS. Apathy: Concept, Syndrome, Neural Mechanisms, and Treatment. Semin Clin Neuropsychiatry 1996;1(4):304-314.
Martinez-Fernandez R, Pelissier P, Quesada JL, et al. Postoperative apathy can neutralise benefits in quality of life after subthalamic stimulation for Parkinson's disease. J Neurol Neurosurg Psychiatry 2016;87(3):311-318.
Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 2006;16(7):916-928.
Chagraoui A, Boukhzar L, Thibaut F, Anouar Y, Maltete D. The pathophysiological mechanisms of motivational deficits in Parkinson's disease. Progr Neuropsychopharmacol Biol Psychiatry 2018;81:138-152.
Chaudhuri KR, Odin P. The challenge of non-motor symptoms in Parkinson's disease. Prog Brain Res 2010;184:325-341.
Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 2015;14(5):518-531.
Sierra M, Carnicella S, Strafella AP, et al. Apathy and Impulse Control Disorders: Yin & Yang of Dopamine Dependent Behaviors. J Parkinsons Dis 2015;5(3):625-636.
Maier F, Lewis CJ, Horstkoetter N, et al. Subjective perceived outcome of subthalamic deep brain stimulation in Parkinson's disease one year after surgery. Parkinsonism Relat Disord 2016;24:41-47.
Maier F, Lewis CJ, Horstkoetter N, et al. Patients’ expectations of deep brain stimulation, and subjective perceived outcome related to clinical measures in Parkinson's disease: a mixed-method approach. J Neurol Neurosurg Psychiatry 2013;84(11):1273-1281.
Aarsland D, Bronnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 2009;80(8):928-930.
Abbes M, Lhommee E, Thobois S, et al. Subthalamic stimulation and neuropsychiatric symptoms in Parkinson's disease: results from a long-term follow-up cohort study. J Neurol Neurosurg Psychiatry 2018;89(8):836-843.
Drapier D, Peron J, Leray E, et al. Emotion recognition impairment and apathy after subthalamic nucleus stimulation in Parkinson's disease have separate neural substrates. Neuropsychologia 2008;46(11):2796-2801.
Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008;7(7):605-614.
Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010;133(Pt 4):1111-1127.
Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013;136(Pt 5):1568-1577.
Czernecki V, Schupbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 2008;23(7):964-969.
Magnard R, Vachez Y, Carcenac C, et al. What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease? Transl Psychiatry 2016;6:e753.
Drapier D, Drapier S, Sauleau P, et al. Does subthalamic nucleus stimulation induce apathy in Parkinson's disease? J Neurol 2006;253(8):1083-1091.
Le Jeune F, Drapier D, Bourguignon A, et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 2009;73(21):1746-1751.
Zoon TJ, de Bie RM, Schuurman PR, van den Munckhof P, Denys D, Figee M. Resolution of apathy after dorsal instead of ventral subthalamic deep brain stimulation for Parkinson's disease. J Nneurol 2019;266(5):1267-1269.
Breysse E, Pelloux Y, Baunez C. The good and bad differentially encoded within the subthalamic nucleus in rats(1,2,3). eNeuro 2015;2(5): pii: ENEURO.0014-15.2015.
Darbaky Y, Baunez C, Arecchi P, Legallet E, Apicella P. Reward-related neuronal activity in the subthalamic nucleus of the monkey. Neuroreport 2005;16(11):1241-1244.
Espinosa-Parrilla JF, Baunez C, Apicella P. Modulation of neuronal activity by reward identity in the monkey subthalamic nucleus. Eur J Neurosci 2015;42(1):1705-1717.
Lardeux S, Pernaud R, Paleressompoulle D, Baunez C. Beyond the reward pathway: coding reward magnitude and error in the rat subthalamic nucleus. J Neurophysiol 2009;102(4):2526-2537.
Montanari C, Giorla E, Pelloux Y, Baunez C. Subthalamic nucleus mediates the modulation on cocaine self-administration induced by ultrasonic vocalization playback in rats. Addict Biol 2020;25(1):e12710.
Lardeux S, Paleressompoulle D, Pernaud R, Cador M, Baunez C. Different populations of subthalamic neurons encode cocaine vs. sucrose reward and predict future error. J Neurophysiol 2013;110(7):1497-1510.
Justin Rossi P, Peden C, Castellanos O, Foote KD, Gunduz A, Okun MS. The human subthalamic nucleus and globus pallidus internus differentially encode reward during action control. Hum Brain Mapp 2017;38(4):1952-1964.
Zenon A, Duclos Y, Carron R, et al. The human subthalamic nucleus encodes the subjective value of reward and the cost of effort during decision-making. Brain 2016;139(Pt 6):1830-1843.
Baunez C, Amalric M, Robbins TW. Enhanced food-related motivation after bilateral lesions of the subthalamic nucleus. J Neurosci 2002;22(2):562-568.
Baunez C, Dias C, Cador M, Amalric M. The subthalamic nucleus exerts opposite control on cocaine and ‘natural’ rewards. Nat Neurosci 2005;8(4):484-489.
Bezzina G, Boon FS, Hampson CL, et al. Effect of quinolinic acid-induced lesions of the subthalamic nucleus on performance on a progressive-ratio schedule of reinforcement: a quantitative analysis. Behav Brain Res 2008;195(2):223-230.
Uslaner JM, Dell'Orco JM, Pevzner A, Robinson TE. The influence of subthalamic nucleus lesions on sign-tracking to stimuli paired with food and drug rewards: facilitation of incentive salience attribution? Neuropsychopharmacology 2008;33(10):2352-2361.
Maillard CA, Edwards DA. [Subthalamic lesions eliminate sexual behavior in the male rat]. J Physiol (Paris) 1988;83(1):50-55.
Pratt WE, Choi E, Guy EG. An examination of the effects of subthalamic nucleus inhibition or mu-opioid receptor stimulation on food-directed motivation in the non-deprived rat. Behav Brain Res 2012;230(2):365-373.
Eusebio A, Witjas T, Cohen J, et al. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease. J Neurol Neurosurg Psychiatry 2013;84(8):868-874.
Lhommee E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain 2012;135(Pt 5):1463-1477.
Pelloux Y, Degoulet M, Tiran-Cappello A, et al. Subthalamic nucleus high frequency stimulation prevents and reverses escalated cocaine use. Mol Psychiatry 2018;23(12):2266-2276.
Rouaud T, Lardeux S, Panayotis N, Paleressompoulle D, Cador M, Baunez C. Reducing the desire for cocaine with subthalamic nucleus deep brain stimulation. Proc Natl Acad Sci U S A 2010;107(3):1196-1200.
Adams WK, Vonder Haar C, Tremblay M, et al. Deep-brain stimulation of the subthalamic nucleus selectively decreases risky choice in risk-preferring rats. eNeuro 2017;4(4).
Hachem-Delaunay S, Fournier ML, Cohen C, et al. Subthalamic nucleus high-frequency stimulation modulates neuronal reactivity to cocaine within the reward circuit. Neurobiol Dis 2015;80:54-62.
Wade CL, Kallupi M, Hernandez DO, et al. High-frequency stimulation of the subthalamic nucleus blocks compulsive-like re-escalation of heroin taking in rats. Neuropsychopharmacology 2017;42(9):1850-1859.
Creed M. Current and emerging neuromodulation therapies for addiction: insight from pre-clinical studies. Curr Opin Neurobiol 2018;49:168-174.
Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009;24(11):1641-1649.
Pagonabarraga J, Kulisevsky J. Apathy in Parkinson's disease. Int Rev Neurobiol 2017;133:657-678.
Castelli L, Perozzo P, Zibetti M, et al. Chronic deep brain stimulation of the subthalamic nucleus for Parkinson's disease: effects on cognition, mood, anxiety and personality traits. Eur Neurol 2006;55(3):136-144.
Temel Y, Boothman LJ, Blokland A, et al. Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus. Proc Natl Acad Sci U S A 2007;104(43):17087-17092.
Temel Y, Tan S, Vlamings R, et al. Cognitive and limbic effects of deep brain stimulation in preclinical studies. Front Biosci 2009;14:1891-1901.
Czernecki V, Pillon B, Houeto JL, et al. Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease? J Neurol Neurosurg Psychiatry 2005;76(6):775-779.
Robert GH, Le Jeune F, Lozachmeur C, et al. Preoperative factors of apathy in subthalamic stimulated Parkinson disease: a PET study. Neurology 2014;83(18):1620-1626.
Wang Y, Li Y, Zhang X, Xie A. Apathy following bilateral deep brain stimulation of subthalamic nucleus in Parkinson's disease: a meta-analysis. Parkinsons Dis 2018;2018:9756468.
Forni C, Mainard O, Melon C, Goguenheim D, Kerkerian-Le Goff L, Salin P. Portable microstimulator for chronic deep brain stimulation in freely moving rats. J Neurosci Meth 2012;209(1):50-57.
Drui G, Carnicella S, Carcenac C, et al. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease. Mol Psychiatry 2014;19(3):358-367.
Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther 2009;31(1):89-98.
Favier M, Duran T, Carcenac C, Drui G, Savasta M, Carnicella S. Pramipexole reverses Parkinson's disease-related motivational deficits in rats. Mov Disord 2014;29(7):912-920.
Carcenac C, Favier M, Vachez Y, et al. Subthalamic deep brain stimulation differently alters striatal dopaminergic receptor levels in rats. Mov Disord 2015;30(13):1739-1749.
Tokunaga N, Choudhury ME, Nishikawa N, et al. Pramipexole upregulates dopamine receptor D(2) and D(3) expression in rat striatum. J Pharmacol Sci 2012;120(2):133-137.
Micallef J, Rey M, Eusebio A, et al. Antiparkinsonian drug-induced sleepiness: a double-blind placebo-controlled study of L-dopa, bromocriptine and pramipexole in healthy subjects. Br J Clin Pharmacol 2009;67(3):333-340.
Castelli L, Lanotte M, Zibetti M, et al. Apathy and verbal fluency in STN-stimulated PD patients. An observational follow-up study. J Neurol 2007;254(9):1238-1243.
Funkiewiez A, Ardouin C, Caputo E, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75(6):834-839.
Gervais-Bernard H, Xie-Brustolin J, Mertens P, et al. Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: five year follow-up. J Neurol 2009;256(2):225-233.
Schupbach WM, Chastan N, Welter ML, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry 2005;76(12):1640-1644.
Temel Y, Visser-Vandewalle V, van der Wolf M, et al. Monopolar versus bipolar high frequency stimulation in the rat subthalamic nucleus: differences in histological damage. Neurosci Lett 2004;367(1):92-96.
Chaturvedi A, Lujan JL, McIntyre CC. Artificial neural network based characterization of the volume of tissue activated during deep brain stimulation. J Neural Eng 2013;10(5):056023.
Creed MC, Hamani C, Nobrega JN. Effects of repeated deep brain stimulation on depressive- and anxiety-like behavior in rats: comparing entopeduncular and subthalamic nuclei. Brain Stimul 2013;6(4):506-514.
Aleksandrova LR, Creed MC, Fletcher PJ, Lobo DS, Hamani C, Nobrega JN. Deep brain stimulation of the subthalamic nucleus increases premature responding in a rat gambling task. Behav Brain Res 2013;245:76-82.
Darbaky Y, Forni C, Amalric M, Baunez C. High frequency stimulation of the subthalamic nucleus has beneficial antiparkinsonian effects on motor functions in rats, but less efficiency in a choice reaction time task. Eur J Neurosci 2003;18(4):951-956.
Abulseoud OA, Kasasbeh A, Min HK, et al. Stimulation-induced transient nonmotor psychiatric symptoms following subthalamic deep brain stimulation in patients with Parkinson's disease: association with clinical outcomes and neuroanatomical correlates. Stereotact Funct Neurosurg 2016;94(2):93-101.
Simmons DB, Dashtipour K. The quantitative measurement of reversible acute depression after subthalamic deep brain stimulation in a patient with Parkinson disease. Case Rep Neurol Med 2015;2015:165846.
Alkemade A, Schnitzler A, Forstmann BU. Topographic organization of the human and non-human primate subthalamic nucleus. Brain Struct Funct 2015;220(6):3075-3086.
Lambert C, Zrinzo L, Nagy Z, et al. Confirmation of functional zones within the human subthalamic nucleus: patterns of connectivity and sub-parcellation using diffusion weighted imaging. Neuroimage 2012;60(1):83-94.
Mallet L, Schupbach M, N'Diaye K, et al. Stimulation of subterritories of the subthalamic nucleus reveals its role in the integration of the emotional and motor aspects of behavior. Proc Natl Acad Sci U S A 2007;104(25):10661-10666.
Stefurak T, Mikulis D, Mayberg H, et al. Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: a functional MRI case study. Mov Disord 2003;18(12):1508-1516.
Roji R, Centeno C. The use of methylphenidate to relieve fatigue. Curr Opin Support Palliat Care 2017;11(4):299-305.
Skorvanek M, Gdovinova Z, Rosenberger J, et al. The associations between fatigue, apathy, and depression in Parkinson's disease. Acta Neurol Scand 2015;131(2):80-87.
Benazzouz A, Gao D, Ni Z, Benabid AL. High frequency stimulation of the STN influences the activity of dopamine neurons in the rat. Neuroreport 2000;11(7):1593-1596.
Min HK, Ross EK, Jo HJ, et al. Dopamine release in the nonhuman primate caudate and putamen depends upon site of stimulation in the subthalamic nucleus. J Neurosci 2016;36(22):6022-6029.
Bruet N, Windels F, Bertrand A, Feuerstein C, Poupard A, Savasta M. High frequency stimulation of the subthalamic nucleus increases the extracellular contents of striatal dopamine in normal and partially dopaminergic denervated rats. J Neuropathol Exp Neurol 2001;60(1):15-24.
Kocabicak E, Jahanshahi A, Schonfeld L, Hescham SA, Temel Y, Tan S. Deep brain stimulation of the rat subthalamic nucleus induced inhibition of median raphe serotonergic and dopaminergic neurotransmission. Turk Neurosurg 2015;25(5):721-727.
Zhao XD, Cao YQ, Liu HH, Li FQ, You BM, Zhou XP. Long term high frequency stimulation of STN increases dopamine in the corpus striatum of hemiparkinsonian rhesus monkey. Brain Res 2009;1286:230-238.
Belin D, Everitt BJ. Cocaine seeking habits depend upon dopamine-dependent serial connectivity linking the ventral with the dorsal striatum. Neuron 2008;57(3):432-441.
Haber SN, Knutson B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology 2010;35(1):4-26.
Bjorklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci 2007;30(5):194-202.
Gittis AH, Kreitzer AC. Striatal microcircuitry and movement disorders. Trends Neurosci 2012;35(9):557-564.
Sesack SR, Grace AA. Cortico-basal ganglia reward network: microcircuitry. Neuropsychopharmacology 2010;35(1):27-47.
Simon MJ, Higuera-Matas A, Roura-Martinez D, et al. Changes in D1 but not D2 dopamine or mu-opioid receptor expression in limbic and motor structures after lateral hypothalamus electrical self-stimulation: a quantitative autoradiographic study. Neurobiol Learn Mem 2016;127:17-26.
Le Foll B, Goldberg SR, Sokoloff P. The dopamine D3 receptor and drug dependence: effects on reward or beyond? Neuropharmacology 2005;49(4):525-541.
Simpson EH, Winiger V, Biezonski DK, Haq I, Kandel ER, Kellendonk C. Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition. Biol Psychiatry 2014;76(10):823-831.
Drew MR, Simpson EH, Kellendonk C, et al. Transient overexpression of striatal D2 receptors impairs operant motivation and interval timing. J Neurosci 2007;27(29):7731-7739.
Trifilieff P, Feng B, Urizar E, et al. Increasing dopamine D2 receptor expression in the adult nucleus accumbens enhances motivation. Mol Psychiatry 2013;18(9):1025-1033.
Ishibashi K, Ishii K, Oda K, Mizusawa H, Ishiwata K. Binding of pramipexole to extrastriatal dopamine D2/D3 receptors in the human brain: a positron emission tomography study using 11C-FLB 457. PLoS One 2011;6(3):e17723.
Knight EJ, Testini P, Min HK, et al. Motor and nonmotor circuitry activation induced by subthalamic nucleus deep brain stimulation in patients with Parkinson disease: intraoperative functional magnetic resonance imaging for deep brain stimulation. Mayo Clin Proc 2015;90(6):773-785.
Carriere N, Besson P, Dujardin K, et al. Apathy in Parkinson's disease is associated with nucleus accumbens atrophy: a magnetic resonance imaging shape analysis. Mov Disord 2014;29(7):897-903.
JS, Scholtissen B, Weber WE, Aalten P, Verhey FR, Leentjens AF. Neuroanatomical correlates of apathy in Parkinson's disease: a magnetic resonance imaging study using voxel-based morphometry. Mov Disord 2010;25(14):2318-2325.
Maillet A, Krack P, Lhommee E, et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease. Brain 2016;139(Pt 9):2486-2502.
Creed MC, Hamani C, Bridgman A, Fletcher PJ, Nobrega JN. Contribution of decreased serotonin release to the antidyskinetic effects of deep brain stimulation in a rodent model of tardive dyskinesia: comparison of the subthalamic and entopeduncular nuclei. J Neurosci 2012;32(28):9574-9581.
Chang WL, Breier MR, Yang A, Swerdlow NR. Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague-Dawley rats. Pharmacol Biochem Behav 2011;99(4):634-638.
Riddle JL, Rokosik SL, Napier TC. Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls. Behav Brain Res 2012;233(1):15-23.
Favier M, Carcenac C, Drui G, et al. Implication of dorsostriatal D3 receptors in motivational processes: a potential target for neuropsychiatric symptoms in Parkinson's disease. Sci Rep 2017;7:41589.
Hurley MJ, Jenner P. What has been learnt from study of dopamine receptors in Parkinson's disease? Pharmacol Ther 2006;111(3):715-728.
Marin-Lahoz J, Pagonabarraga J, Martinez-Horta S, et al. Parkinson's disease: impulsivity does not cause impulse control disorders but boosts their severity. Front Psychiatry 2018;9:465.
Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010;67(5):589-595.
Houeto JL, Magnard R, Dalley JW, Belin D, Carnicella S. Trait impulsivity and anhedonia: two gateways for the development of impulse control disorders in Parkinson's disease? Front Psychiatry 2016;7:91.
Belin D, Mar AC, Dalley JW, Robbins TW, Everitt BJ. High impulsivity predicts the switch to compulsive cocaine-taking. Science 2008;320(5881):1352-1355.
Scangos KW, Shahlaie K. Acute frequency-dependent hypomania induced by ventral subthalamic nucleus deep brain stimulation in Parkinson's disease: a case report. Biol Psychiatry 2017;82(5):e39-e41.
Welter ML, Schupbach M, Czernecki V, et al. Optimal target localization for subthalamic stimulation in patients with Parkinson disease. Neurology 2014;82(15):1352-1361.
Pelloux Y, Meffre J, Giorla E, Baunez C. The subthalamic nucleus keeps you high on emotion: behavioral consequences of its inactivation. Front Behav Neurosci 2014;8:414.
Ardouin C, Voon V, Worbe Y, et al. Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord 2006;21(11):1941-1946.
Bandini F, Primavera A, Pizzorno M, Cocito L. Using STN DBS and medication reduction as a strategy to treat pathological gambling in Parkinson's disease. Parkinsonism Relat Disord 2007;13(6):369-371.
Knobel D, Aybek S, Pollo C, Vingerhoets FJ, Berney A. Rapid resolution of dopamine dysregulation syndrome (DDS) after subthalamic DBS for Parkinson disease (PD): a case report. Cogn Behav Neurol 2008;21(3):187-189.
Witjas T, Baunez C, Henry JM, et al. Addiction in Parkinson's disease: impact of subthalamic nucleus deep brain stimulation. Mov Disord 2005;20(8):1052-1055.
Castrioto A, Carnicella S, Fraix V, Chabardes S, Moro E, Krack P. Reversing dopaminergic sensitization. Mov Disord 2017;32(12):1679-1683.
Pelloux Y, Baunez C. Deep brain stimulation for addiction: why the subthalamic nucleus should be favored. Curr Opin Neurobiol 2013;23(4):713-720.
Tan SK, Janssen ML, Jahanshahi A, et al. High frequency stimulation of the subthalamic nucleus increases c-fos immunoreactivity in the dorsal raphe nucleus and afferent brain regions. J Psychiatr Res 2011;45(10):1307-1315.
Martinez D, Gil R, Slifstein M, et al. Alcohol dependence is associated with blunted dopamine transmission in the ventral striatum. Biol Psychiatry 2005;58(10):779-786.
Barak S, Carnicella S, Yowell QV, Ron D. Glial cell line-derived neurotrophic factor reverses alcohol-induced allostasis of the mesolimbic dopaminergic system: implications for alcohol reward and seeking. J Neurosci 2011;31(27):9885-9894.
Martinez D, Greene K, Broft A, et al. Lower level of endogenous dopamine in patients with cocaine dependence: findings from PET imaging of D(2)/D(3) receptors following acute dopamine depletion. Am J Psychiatry 2009;166(10):1170-1177.
Le Moal M, Koob GF. Drug addiction: pathways to the disease and pathophysiological perspectives. Eur Neuropsychopharmacol 2007;17(6-7):377-393.
Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press; 1998.